ArticleNature medicine2024
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity.
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Intervening Early in the Cardiovascular-Kidney-Metabolic Syndrome: Expert Recommendations from the United Arab Emirates on the Management of Prediabetes.Vascular health and risk management · 2026Guideline
- Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.Annals of clinical and translational neurology · 2026Review
- Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.Surgical endoscopy · 2026Article
- Causes and consequences of discontinuation of GLP1RAs or tirzepatide.Nature reviews. Endocrinology · 2026Review
- Article
- Incretin therapies, nutrition and food insecurity in the UK.Nature medicine · 2026Article
- Assessing the impact of pharmacist-led interventions on glucagon-like peptide 1 receptor agonist access and treatment outcomes.Journal of managed care & specialty pharmacy · 2026Article
- Article
- Beyond weight loss: Integrating GLP-1 RA therapies into psychological and behavioral care for obesity and binge eating disorder.Reviews in endocrine & metabolic disorders · 2026Review
- Smoking cessation and weight loss before ventral hernia repair - can we really justify this? A single center cohort study.Hernia : the journal of hernias and abdominal wall surgery · 2026Article
- Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026Review
- GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.Annals of medicine and surgery (2012) · 2026Article
- Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers.Healthcare (Basel, Switzerland) · 2026Article
- Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series.Case reports in pediatrics · 2026Article
- Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation.Drug design, development and therapy · 2026Review
- Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence.Molecular psychiatry · 2026Review
- Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation.Healthcare (Basel, Switzerland) · 2025Article
- Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.World journal of gastroenterology · 2025Review
- How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women's Health, Nontraditional Access, and Barriers to Access: Content Analysis.Journal of medical Internet research · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.